Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Oct - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares
Source: Bse
Gufic Biosciences Limited (GUFICBIO)
Small CapPharma stocks · Small cap · NSE
Gufic Biosciences Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result14 Aug, 07:45 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
70BullishSMA20 -1.3% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 51
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
GUFICBIOD candles · FIT view+35.6%Latest close ₹404.45 on 2026-10-19
Bar
-1.8%
RSI
42
MACD hist
-2.22
52W pos
68%
2026-10-19O ₹412.00H ₹418.20L ₹402.00C ₹404.45Vol 64,283 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
GUFICBIONifty PharmaNifty 500
- GUFICBIO
- +2.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +8.3 pp
Chart stats
19 Oct 2026- From 52W high
- -13.5%
- 52W range position
- 68%
- ATR (14)
- 4.1%
- Volume vs 20D
- 0.82x
- Avg traded value
- ₹3.3 Cr
- 20D price channel
- ₹399.5 - ₹452
₹467.8
₹268 - ₹467.8
₹16.5
Latest completed session
20-session average
33.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED28
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +16.5% · PAT +69.2% YoY
Technical
Bullish70
Price trend and sector-relative-strength timing.
Valuation
Legacy model-22.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence71
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +17% YoY · PAT +69% YoY · margin expansion · operating leverage
Filed 14 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹261 Cr | +16.5% | +3.6% |
| EBITDA | ₹47 Cr | +42.4% | +0.0% |
| Operating margin | 18.0% | +300 bps | -100 bps |
| PAT | ₹22 Cr | +69.2% | +0.0% |
| PAT margin | 8.4% | +263 bps | -30 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 57.30
- P/B
- 6.33
- EV/EBITDA
- 23.54
- Market Cap
- 4209.00Cr
Profitability
- ROE
- 10.10%
- ROCE
- 12.30%
- ROA
- 5.44%
- Dividend Y
- 0.02%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 16.00%
- Revenue 3Y
- 13.00%
- EPS 3Y
- 13.00%
Balance Sheet
- Debt/Equity
- 0.61
- Interest Coverage
- 4.46×
- Altman Z
- 5.73
- Book Value
- 66.30
Cash Flow
- FCF Yield
- 0.33%
- FCF Positive Y
- 2/5
- OCF
- 45.00 Cr
- EPS TTM
- 7.32
Shareholding
- Promoter Hold
- 72.50%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 76%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 261+3.6% vs prev
Net Profit
₹ CrLatest: 22.0+0.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 42.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~1.3% over last month) — short-term momentum negative.
- RSI(14) at 42 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 14% off 52W high · 51% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
81
RS percentile
Stage 2 UptrendEstablished S2
1M return
-7.2%
3M return
+2.7%
6M return
+39.3%
1Y return
+19.9%
RS 1D
+1
RS 20D
+1
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 10.8% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +5.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
17 Jun 2026
S2 age
87 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 116.42+1.02%
RS vs Nifty 500116
Valuation & peers
U-Score 28 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 28 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation0/30
Growth11/25
Quality2/20
Balance Sheet8/15
Cash Flow2/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
28
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
28/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 8/15 to the score.
- Growth contributes 11/25 to the score.
Main drags
- Fair-value margin of safety is negative at -22.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 2/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
57.3
PB
6.3
EV/EBITDA
23.5
ROE
10.1%
ROCE
12.3%
FCF Yield
0.3%
Debt/Equity
0.6
MoS
-22.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
28
Previous: 28
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-22.8%
Previous: -22.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
28
28
28
28
28
28
28
28
28
28
28
28
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹104.5
-287.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹329.4
-22.8% MoS
PEG
3.87
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ZOTA
Small
Zota Health Care LImited
Pharmaceuticals
match 167
26
—
-15.0%
—
OVERVALUED
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 165
40
49.7
11.6%
-8%
WATCHLIST
FDC
Small
FDC Limited
Pharmaceuticals
match 164
40
17.5
11.2%
-180%
WATCHLIST
BETA
Small
Beta Drugs Limited
Pharmaceuticals
match 162
44
48.7
18.8%
+13%
WATCHLIST
ALEMBICLTD
Small
Alembic Limited
Pharmaceuticals
match 162
58
8.4
13.0%
-21%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Gufic Biosciences Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
71Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 66th percentile of the scored universe and 54th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
64 docs text-extracted · 24 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
66th percentile
overall median 67 · Pharma: 54th pctile, median 70 · Small: 69th pctile, median 66
Evidence depth
Financial-only
64 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
60
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 72.5%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.3%.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Gufic Biosciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 8 Sep - CRISIL reaffirmed Gufic BioSciences' A-/Stable and A2+ ratings; bank facilities increased to Rs. 516 crore.
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Aug - Newspaper advertisement regarding Special Window for re-lodgement of transfer and dematerialization of physical shares is attached herewith
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Acquisition 14 Aug - Board approved Philippines subsidiary incorporation and up to USD 250,000 equity investment.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Jul - Newspaper Advertisement regarding Notice for transfer of equity shares to Investor Education and Protection Fund (IEPF) Authority is attached herewith
Source: Bse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Bse
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Aug - Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 is attached herewith.
Source: Bse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Jun - Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.